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Plasma membrane glycoproteins are involved in cell-matrix interactions. For identification of such glyco- 
proteins a recently developed cell system was used. Two cell populations differing in their adhesion proper- 
ties were selected from Morris hepatoma 7777. One population was able to grow as a monolayer, while 
the other proliferated in suspension. From both cell lines spontaneous revertants were selected. By using 
antibodies raised against plasma membranes of the hepatoma and of rat liver for sequential immunoprecipi- 
tation a glycoprotein of M, 110 000 was identified. This glycoprotein was only expressed in adherent hepato- 
ma cells as well as in normal rat liver, but was absent in non-adherent hepatoma cells and in the in vivo 
growing Morris hepatoma 7777. This suggests that the glycoprotein is involved in cell-substratum adhesion 
of hepatocytes and adherent hepatoma cells. 
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1. INTRODUCTION 
The interaction of cells with substances of the 
extracellular matrix is a complex process in which 
several membrane components of different func- 
tions are involved. Membrane glycoproteins 
mediating adhesion to extracellular factors such as 
fibronectin [l-4], laminin [5,6], vitronectin [7] 
and collagen [8] have been identified. Other mem- 
brane components are thought to be responsible 
for motility [9] or matrix assembly [lo]. Recently 
we have shown that hepatocytes express at least 
three glycoproteins, which are involved in cell- 
substratum adhesion. Two of these glycoproteins 
were separated by size-exclusion HPLC and block- 
ed the adhesion-inhibiting activity of antibodies 
raised against the plasma membranes of liver and 
hepatomas [l I]. Antibodies raised against a third 
glycoprotein inhibited the initial adhesion of 
hepatocytes [121. This glycoprotein was identified 
as dipeptidyl peptidase IV (DPP IV). We have also 
shown that an adhesion-involved glycoprotein with 
an apparent M, of 105000 as well as the DPP IV 
were lost or markedly reduced in Morris hepatoma 
7777 [11,13]. 
For further identification and characterization 
of adhesion-involved molecules a cell system was 
established which allowed the determination of 
molecular alterations associated with the transition 
of an adherent o a non-adherent phenotype [14]. 
By propagation of cells isolated directly from the 
solid Morris hepatoma 7777 an adherent and a 
non-adherent cell variant have been obtained 
[15,16]. To provide a conclusive relation between 
a molecular alteration and adhesiveness, addi- 
tionally spontaneous revertants were selected from 
the two directly isolated cell lines [14]. Thus, two 
adherent and two non-adherent cell lines of the 
same cellular origin were compared with their nor- 
mal counterparts, i.e. rat hepatocytes. It can be 
assumed that glycoproteins expressed in 
hepatocytes and adherent variants of Morris 
hepatoma 7777, but not expressed in both non- 
adherent variants, are involved in cell-substratum 
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adhesion. Here, a 110 kDa glycoprotein is de- 
scribed which is not identical with DPP IV and is 
expressed only in adherent cell variants and in nor- 
mal hepatocytes. It is therefore suggested, that this 
glycoprotein is involved in cell-substratum 
adhesion. 
2. MATERIALS AND METHODS 
2.1. Cells and cell culture conditions 
The cultivation of an adherent and a non- 
adherent cell line from Morris hepatoma 7777 
isolated from the solid carcinoma has been de- 
scribed [ 15,161. The establishment of the revertant 
cell lines is described in [ 141. All cell lines were pro- 
pagated in Dulbecco’s modification of Eagle’s 
medium (DMEM) containing 10% serum, lo-* M 
insulin and 10m6 M dexamethasone. 
2.2. Adhesion-inhibiting assay 
The preparation of broad spectrum antisera 
raised against plasma membranes of rat liver (anti- 
liver antibodies) and Morris hepatoma 7777 (anti- 
hepatoma antibodies) has been described [151. The 
adhesion-inhibiting assay was performed essential- 
ly as in [17]. Briefly, various concentrations of an 
IgG preparation isolated from anti-liver or anti- 
hepatoma antiserum were added to lo4 freshly 
passaged cells. The cells were seeded on coated 
plates in serum-free DMEM for collagen-, 
vitronectin- and fibronectin-mediated adhesion, or 
in DMEM containing 10% fetal calf serum for 
serum-mediated adhesion on uncoated plates. 
Fibronectin and collagen I isolation and the 
coating of tissue culture plates were carried out by 
standard methods [l&19]. Collagen IV isolated 
from human placenta was purchased from Sigma. 
Vitronectin (serum spreading factor) was a gift 
from Dr D. Barnes, Corvallis, OR. Inhibition of 
cell-substratum adhesion was evaluated after com- 
plete spreading of untreated control cultures, i.e. 
after 3 h for adhesion on fibronectin or collagen I 
and IV, and after overnight incubation for serum- 
and vitronectin-mediated adhesion. 
2.3. Immunoprecipitation and immunodepletion 
For metabolic labeling lo6 cells were seeded in 
10 ml serum-free medium containing 50 ,&i 
[3H]glucosamine (D-[6-3H]glucosamine hydro- 
chloride, 30 Ci/mmol, Amersham). After 8 h in- 
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cubation the cells were washed with phosphate- 
buffered saline (0.9% NaCl, pH 7.2) and solubiliz- 
ed in 1 ml buffer A (10 mM Tris-HCl, pH 7.8, 
containing 150 mM NaCl, 1 mM CaC12, 1 mM 
MgClz, 1 mM phenylmethylsulfonyl fluoride and 
1% Nonidet P40). The cells were homogenized in 
a Potter-type homogenizer (800 rpm, 8 strokes) 
and then ultracentrifuged at 100000 x g for 
30 min. The supernatant (500~1) was diluted with 
4.5 ml buffer A without Nonidet P40 and 50 ~1 an- 
tiserum were added. After an overnight incubation 
with 20 mg protein A-Sepharose (Sigma) the pellet 
was washed 3 times with buffer A, twice with 
phosphate-buffered saline and once with water. 
Specifically bound glycoproteins were solubilized 
in sample buffer according to Laemmli [20] and 
subjected to SDS gel electrophoresis. Fluoro- 
graphic analysis was carried out as described by 
Laskey and Mills [21]. For the immunodepletion 
experiment anti-hepatoma antibodies were added 
to the cell solubilisates. After the first immuno- 
precipitation again anti-hepatoma ntibodies were 
added to the supernatant. The procedure was re- 
peated until practically no radioactivity was pre- 
cipitated by the anti-hepatoma ntibodies. In the 
last step anti-liver antibodies were added instead of 
anti-hepatoma ntibodies. 
3. RESULTS AND DISCUSSION 
Plasma membrane glycoconjugates are assumed 
to mediate cell-substratum adhesion. Such 
glycoproteins present in adherent hepatoma cells 
would be altered or not expressed in non-adherent 
hepatoma cells. It can be assumed that these 
adhesion-involved molecules are also present in the 
normal counterparts of rat hepatoma cells, i.e. rat 
hepatocytes. Recently we have shown that an- 
tibodies against plasma membranes of rat liver 
(anti-liver antibodies) are able to inhibit serum- 
mediated adhesion of hepatocytes or adhesion on 
culture plates coated with vitronectin (serum 
spreading factors), fibronectin or collagen 
[11,15,17]. On the other hand, antibodies against 
plasma membranes of Morris hepatoma 7777 
(anti-hepatoma antibodies) only inhibited adhe- 
sion of hepatocytes on fibronectin and collagen. 
They did not inhibit serum-mediated adhesion or 
adhesion on vitronectin. Similar results were ob- 
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tained when adherent hepatoma cells were used in- 
stead of hepatocytes (table 1). Thus, the anti- 
hepatoma antibodies do not inhibit vitronectin- or 
serum-mediated adhesion of adherent hepatoma 
cells. This suggests that adherent hepatoma cells 
express a membrane component involved in serum- 
mediated adhesion, which is absent in the 
hepatoma in vivo. However, since anti-liver an- 
tibodies inhibit this type of adhesion of the 
hepatoma cells, this membrane component seems 
to be present in normal rat liver. 
The different inhibitory specificities of the an- 
tibodies raised the possibility of identifying those 
membrane components which are expressed in nor- 
mal rat liver plasma membrane, but are lost in the 
plasma membrane of Morris hepatoma 7777. Con- 
sequently, they would be re-expressed in the 
adherent populations of the hepatoma cells. The 
anti-hepatoma antibodies were used to im- 
munoprecipitate all proteins from adherent cells, 
which were common for this hepatoma and for in 
vivo growing hepatoma cells. Proteins present in 
adherent hepatoma cells, but absent in the in vivo 
growing hepatoma should remain in the superna- 
tant of the immunoprecipitation. Subsequently, 
immunoprecipitation with the anti-liver antibodies 
was used to precipitate membrane proteins com- 
Table 1 
Inhibition of adhesion by antibodies raised against 
plasma membranes of rat liver (anti-liver antibodies) or 
Morris hepatoma 7777 (anti-hepatoma antibodies) 
Substratum Anti-liver Anti-hepatoma 
antibodies antibodies 
Fibronectin + + 
Collagen I + + 
Collagen IV + + 
Serum spreading factor 
vitronectin + - 
Serum + - 
Adherent hepatoma cells were seeded on plates coated 
with different substrata or in the presence of 10% fetal 
calf serum. The concentration of the antibodies was 
200 pg/ml. Complete inhibition of adhesion ( + ) or lack 
of any effect ( - ) was observed after 3 h on collagens 
and fibronectin or 16 h on vitronectin and in the 
presence of fetal calf serum. Non-adherent hepatoma 
cells were unable to adhere to any of these substrata 
mon to liver cells and adherent hepatoma cells. By 
this procedure only one glycoprotein of 110 kDa 
was immunoprecipitated by the anti-liver an- 
tibodies (fig. 1). Analogous experiments with non- 
adherent cells precipitated no protein in the last 
step. Thus, a 110 kDa protein was identified which 
is only expressed in normal hepatocytes and the 
adherent hepatoma cells, but not in the non- 
adherent and in vivo growing hepatoma cells. This 
suggests that this glycoprotein is associated with 
the adherent phenotype. Beside this difference in 
the expression of a 110 kDa plasma membrane 
glycoprotein other alterations of the membrane 
composition of the four cell lines have been 
a b c d e 
Fig. 1. Polyacrylamide gel electrophoresis of precipitates 
obtained in the immunodepletion experiment using 
[‘Hlglucosamine-labeled adherent hepatoma cells. Anti- 
hepatoma antiserum was added to a cell solubilisate 
together with protein A-Sepharose. After the first 
immunoprecipitation (lane a) anti-hepatoma antiserum 
and protein A-Sepharose were again added to the 
supernatant. This was repeated until no radioactivity 
was precipitated by anti-hepatoma antiserum (lanes 
b-d). In the last step anti-liver antiserum was added 
instead of anti-hepatoma antiserum (lane e). No labeled 
protein was precipitated in the last step when non- 
adherent cells were used. 
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detected ([14] and unpublished). However, most of 
them cannot be related to cell-substratum 
adhesiveness. 
Since we have shown that the ectoenzyme DPP 
IV is involved in cell-substratum adhesion [ 121 and 
expressed in a higher concentration in adherent 
hepatoma cells compared to non-adherent 
hepatoma cells [ 141, it was of interest o exclude or 
to prove the identity of the 110 kDa glycoprotein 
with DPP IV, which has the same molecular mass 
as a monomer. Two lines of evidence showed that 
the 110 kDa glycoprotein and DPP IV are distinct 
entities: (i) anti-hepatoma ntibodies precipitated 
the enzymatic activity of DPP IV, and (ii) addi- 
tionally a monoclonal antibody to DPP IV [22] did 
not yield any precipitated material after im- 
munodepletion with anti-hepatoma antibodies. 
However, from this supernatant the 110 kDa 
glycoprotein could be precipitated with anti-liver 
antibodies. 
On the other hand, it seems likely that the 
110 kDa glycoprotein described here is identical 
with the adhesion-involved molecule of Mr 105000 
identified previously in the liver by size-exclusion 
HPLC [ 111. This glycoprotein was also not 
detected in the plasma membrane of the in vivo 
growing Morris hepatoma. It was suggested that 
the glycoprotein is involved in serum-mediated 
adhesion [171. We have shown that the initial adhe- 
sion of hepatocytes in the presence of serum is 
mediated by serum factors of 60-80 kDa, 
probably vitronectin or ‘serum spreading factors’ 
[17]. A receptor for vitronectin has been identified 
recently as a pair of glycoproteins of Mr 115 000 
and 125 000 [7]. The isolation and further 
characterization of the 110 kDa glycoprotein iden- 
tified by the immunodepletion experiment will 
reveal whether it is related to the vitronectin recep- 
tor glycoproteins. 
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